Citicoline (Tablets, Solution, Powder) Instructions for Use
ATC Code
N06BX06 (Citicoline)
Active Substance
Citicoline (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Nootropic drug
Pharmacotherapeutic Group
Psychoanaleptics; psychostimulants, agents used in attention deficit hyperactivity disorder, and nootropic agents; other psychostimulants and nootropic agents
Pharmacological Action
Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action: it promotes the restoration of damaged cell membranes, inhibits the action of phospholipases, preventing the excessive formation of free radicals, and also prevents cell death by acting on apoptosis mechanisms.
In the acute period of stroke, it reduces the volume of damaged tissue and improves cholinergic transmission.
In traumatic brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms, and also contributes to shortening the duration of the recovery period.
Citicoline is effective in the treatment of cognitive, sensory, and motor neurological disorders of degenerative and vascular etiology.
In chronic cerebral ischemia, Citicoline is effective in treating disorders such as memory impairment, lack of initiative, difficulties in performing daily activities and self-care. It increases the level of attention and consciousness and also reduces the manifestation of amnesia.
Pharmacokinetics
After parenteral administration, the plasma concentration of choline increases significantly. Citicoline is largely distributed in the structures of the brain, with rapid incorporation of choline fractions into structural phospholipids and cytidine fractions into cytidine nucleotides and nucleic acids.
Citicoline penetrates the brain and is actively incorporated into cellular, cytoplasmic, and mitochondrial membranes, forming part of the structural phospholipid fraction.
When administered intravenously and intramuscularly, Citicoline is metabolized in the liver to form choline and cytidine. Only 15% of the administered dose of citicoline is excreted from the human body: less than 3% by the kidneys and through the intestines and about 12% in exhaled air.
The urinary excretion of citicoline can be divided into two phases: the first phase, lasting about 36 hours, during which the excretion rate decreases rapidly, and the second phase, during which the excretion rate decreases much more slowly. The same is observed in exhaled air – the excretion rate decreases rapidly after approximately 15 hours and then decreases much more slowly.
Indications
Acute period of ischemic stroke (as part of complex therapy); recovery period of ischemic and hemorrhagic strokes; traumatic brain injury, acute (as part of complex therapy) and recovery period; cognitive and behavioral disorders in degenerative and vascular brain diseases.
ICD codes
| ICD-10 code | Indication |
| F07 | Personality and behavioral disorders due to disease, damage or dysfunction of the brain |
| I63 | Cerebral infarction |
| I69 | Sequelae of cerebrovascular diseases |
| S06 | Intracranial injury |
| T90 | Sequelae of injuries of head |
| ICD-11 code | Indication |
| 6E68 | Secondary emotionally labile personality disorder |
| 6E6Z | Unspecified secondary mental or behavioral syndromes |
| 8B11 | Cerebral ischemic stroke |
| 8B25.Z | Sequelae of cerebrovascular disease, unspecified |
| NA07.Z | Intracranial injury, unspecified |
| NA0Z | Head injury, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally or parenterally (intravenously, intramuscularly).
For intravenous use, administer as a slow injection or drip infusion.
The typical daily dose ranges from 500 mg to 2000 mg.
Adjust the specific dose and duration based on the indication and clinical severity.
For the acute period of ischemic stroke, use a dose of 1000 mg every 12 hours.
Continue treatment for at least 6 weeks.
For traumatic brain injury in the acute phase, administer 1000-2000 mg daily.
For chronic neurological deficits and cognitive disorders, the standard oral dose is 500-1000 mg once or twice daily.
Divide the total daily dose if it exceeds 1000 mg.
Adhere strictly to the prescribed duration of therapy.
Adverse Reactions
Allergic reactions: very rarely – rash, skin itching, anaphylactic shock.
From the nervous system: very rarely – headache, dizziness, insomnia, agitation, hallucinations. In some cases, the drug may stimulate the parasympathetic system and also briefly change blood pressure.
From the digestive system: very rarely – nausea, vomiting, diarrhea, decreased appetite, change in liver enzyme activity.
General reactions: very rarely – feeling of heat, tremor, shortness of breath, numbness in paralyzed limbs, edema.
Contraindications
Hypersensitivity to citicoline; vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system); children and adolescents under 18 years of age.
Use in Pregnancy and Lactation
During pregnancy, use is possible only if the expected benefit of therapy for the mother outweighs the potential risk to the fetus.
If it is necessary to use citicoline during lactation, the issue of discontinuing breastfeeding should be considered, since data on the excretion of citicoline in breast milk are not available.
Pediatric Use
Contraindicated for use in children and adolescents under 18 years of age.
Geriatric Use
Dosage adjustment is not required.
Special Precautions
Citicoline should not be used simultaneously with medicines containing meclofenoxate.
Drug Interactions
Citicoline enhances the effects of levodopa.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Solution for intravenous and intramuscular administration 125 mg/ml: 4 ml amp. 3, 5, 10, 20, 50, or 100 pcs.
Solution for intravenous and intramuscular administration 250 mg/ml: 4 ml amp. 3, 5, 10, 20, 50, or 100 pcs.
Marketing Authorization Holder
AlTro, LLC (Russia)
Manufactured By
Mosfarm LLC (Russia)
Dosage Forms
 |
Citicoline | Solution for intravenous and intramuscular administration 125 mg/ml: 4 ml amp. 3, 5, 10, 20, 50, or 100 pcs. |
| Solution for intravenous and intramuscular administration 250 mg/ml: 4 ml amp. 3, 5, 10, 20, 50, or 100 pcs. |
Dosage Form, Packaging, and Composition
Solution for intravenous and intramuscular administration in the form of a transparent, colorless liquid.
| 1 ml | |
| Citicoline sodium | 130.63 mg, |
| Equivalent to citicoline content | 125 mg |
Excipients : sodium hydroxide solution 1M/hydrochloric acid solution 1M – to pH 6.5-7.5, water for injections – up to 1 ml.
4 ml – ampoules (3) – cardboard packs.
4 ml – ampoules (5) – cardboard packs.
4 ml – ampoules (10) – cardboard packs.
4 ml – ampoules (20) – cardboard packs.
4 ml – ampoules (50) – cardboard packs.
4 ml – ampoules (100) – cardboard packs.
Solution for intravenous and intramuscular administration in the form of a transparent, colorless liquid.
| 1 ml | |
| Citicoline sodium | 261.26 mg, |
| Equivalent to citicoline content | 250 mg |
Excipients : sodium hydroxide solution 1M/hydrochloric acid solution 1M – to pH 6.5-7.5, water for injections – up to 1 ml.
4 ml – ampoules (3) – cardboard packs.
4 ml – ampoules (5) – cardboard packs.
4 ml – ampoules (10) – cardboard packs.
4 ml – ampoules (20) – cardboard packs.
4 ml – ampoules (50) – cardboard packs.
4 ml – ampoules (100) – cardboard packs.
Solution for intravenous and intramuscular administration 125 mg/ml: amp. 4 ml 3, 5, 6, or 10 pcs.
Marketing Authorization Holder
Atoll LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Dosage Form
|
Citicoline | Solution for intravenous and intramuscular administration 125 mg/ml: amp. 4 ml 3, 5, 6, or 10 pcs. |
Dosage Form, Packaging, and Composition
Solution for intravenous and intramuscular administration in the form of a transparent, colorless liquid.
| 1 ml | |
| Citicoline sodium | 130.63 mg, |
| Equivalent to citicoline content | 125 mg |
Excipients : hydrochloric acid 1M – to pH 6.7-7.1, water for injections – up to 1 ml.
4 ml – ampoules of colorless glass (3) – contour cell packaging (1) – cardboard packs.
4 ml – ampoules of colorless glass (3) – contour cell packaging (2) – cardboard packs.
4 ml – ampoules of colorless glass (3) – cardboard trays (1) – cardboard packs.
4 ml – ampoules of colorless glass (3) – cardboard trays (2) – cardboard packs.
4 ml – ampoules of colorless glass (5) – contour cell packaging (1) – cardboard packs.
4 ml – ampoules of colorless glass (5) – contour cell packaging (2) – cardboard packs.
4 ml – ampoules of colorless glass (5) – cardboard trays (1) – cardboard packs.
4 ml – ampoules of colorless glass (5) – cardboard trays (2) – cardboard packs.
Solution for intravenous and intramuscular administration 250 mg/ml: amp. 4 ml 3, 5, 6, or 10 pcs.
Marketing Authorization Holder
Atoll LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Dosage Form
|
Citicoline | Solution for intravenous and intramuscular administration 250 mg/ml: amp. 4 ml 3, 5, 6, or 10 pcs. |
Dosage Form, Packaging, and Composition
Solution for intravenous and intramuscular administration in the form of a transparent, colorless liquid.
| 1 ml | |
| Citicoline sodium | 261.3 mg, |
| Equivalent to citicoline content | 250 mg |
Excipients : hydrochloric acid 1M – to pH 6.7-7.1, water for injections – up to 1 ml.
4 ml – ampoules of colorless glass (3) – contour cell packaging (1) – cardboard packs.
4 ml – ampoules of colorless glass (3) – contour cell packaging (2) – cardboard packs.
4 ml – ampoules of colorless glass (3) – cardboard trays (1) – cardboard packs.
4 ml – ampoules of colorless glass (3) – cardboard trays (2) – cardboard packs.
4 ml – ampoules of colorless glass (5) – contour cell packaging (1) – cardboard packs.
4 ml – ampoules of colorless glass (5) – contour cell packaging (2) – cardboard packs.
4 ml – ampoules of colorless glass (5) – cardboard trays (1) – cardboard packs.
4 ml – ampoules of colorless glass (5) – cardboard trays (2) – cardboard packs.
Solution for intravenous and intramuscular administration 125 mg/ml: amp. 4 ml, 5 pcs per pack.
Solution for intravenous and intramuscular injection 250 mg/ml: amp. 4 ml, 5 pcs per pack.
Marketing Authorization Holder
Belmedpreparaty RUP (Republic of Belarus)
Dosage Forms
|
Citicoline | Solution for intravenous and intramuscular administration 125 mg/ml: amp. 4 ml, 5 pcs per pack. |
| Solution for intravenous and intramuscular injection 250 mg/ml: amp. 4 ml, 5 pcs per pack. |
Dosage Form, Packaging, and Composition
Solution for intravenous and intramuscular administration transparent, colorless or slightly yellowish.
| 1 ml | |
| Citicoline | 125 mg |
| (in terms of Citicoline sodium) | 130.6 mg |
Excipients : sodium hydroxide solution 1 M, hydrochloric acid solution 1 M, water for injections.
4 ml – ampoules (5) – contour cell packaging (1) – cardboard packs.
Solution for intravenous and intramuscular administration transparent, colorless or slightly yellowish.
| 1 ml | |
| Citicoline | 250 mg |
| (in terms of Citicoline sodium) | 261.2 mg |
Excipients : sodium hydroxide solution 1 M, hydrochloric acid solution 1 M, water for injections.
4 ml – ampoules (5) – contour cell packaging (1) – cardboard packs.
Solution for intravenous and intramuscular administration 125 mg/1 ml: amp. 4 ml or 8 ml 5, 10, or 20 pcs.
Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 4 ml 5, 10, or 20 pcs.
Marketing Authorization Holder
Novosibkhimpharm, JSC (Russia)
Dosage Forms
|
Citicoline | Solution for intravenous and intramuscular administration 125 mg/1 ml: amp. 4 ml or 8 ml 5, 10, or 20 pcs. |
| Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 4 ml 5, 10, or 20 pcs. |
Dosage Form, Packaging, and Composition
Solution for intravenous and intramuscular administration in the form of a transparent, colorless or with a yellowish, or brownish, or yellowish-brownish tint liquid.
| 1 ml | |
| Citicoline sodium | 130.63 mg, |
| Equivalent to citicoline content | 125 mg |
Excipients : sodium hydroxide solution 1M or hydrochloric acid solution 1M (for pH adjustment – to 6.0-8.0), water for injections.
4 ml – ampoules of neutral glass (10) – cardboard boxes.
4 ml – ampoules of neutral glass (5) – contour cell packaging (1) – cardboard packs.
4 ml – ampoules of neutral glass (5) – contour cell packaging (2) – cardboard packs.
4 ml – ampoules of neutral glass (10) – contour cell packaging (1) – cardboard packs.
4 ml – ampoules of neutral glass (10) – contour cell packaging (2) – cardboard packs.
8 ml – ampoules of neutral glass (10) – cardboard boxes.
8 ml – ampoules of neutral glass (5) – contour cell packaging (1) – cardboard packs.
8 ml – ampoules of neutral glass (5) – contour cell packaging (2) – cardboard packs.
8 ml – ampoules of neutral glass (10) – contour cell packaging (1) – cardboard packs.
8 ml – ampoules of neutral glass (10) – contour cell packaging (2) – cardboard packs.
Solution for intravenous and intramuscular administration in the form of a transparent, colorless or with a yellowish, or brownish, or yellowish-brownish tint liquid.
| 1 ml | |
| Citicoline sodium | 261.25 mg, |
| Equivalent to citicoline content | 250 mg |
Excipients : sodium hydroxide solution 1M or hydrochloric acid solution 1M (for pH adjustment – to 6.0-8.0), water for injections.
4 ml – ampoules of neutral glass (10) – cardboard boxes.
4 ml – ampoules of neutral glass (5) – contour cell packaging (1) – cardboard packs.
4 ml – ampoules of neutral glass (5) – contour cell packaging (2) – cardboard packs.
4 ml – ampoules of neutral glass (10) – contour cell packaging (1) – cardboard packs.
4 ml – ampoules of neutral glass (10) – contour cell packaging (2) – cardboard packs.
Solution for intravenous and intramuscular administration 125 mg/1 ml: amp. 4 ml 5 or 10 pcs.
Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 4 ml 5 or 10 pcs.
Marketing Authorization Holder
Promomed Rus LLC (Russia)
Manufactured By
Biokhimik, JSC (Russia)
Dosage Forms
|
Citicoline | Solution for intravenous and intramuscular administration 125 mg/1 ml: amp. 4 ml 5 or 10 pcs. |
| Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 4 ml 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Solution for intravenous and intramuscular administration in the form of a transparent, colorless liquid.
| 1 ml | |
| Citicoline sodium | 130.63 mg, |
| Equivalent to citicoline content | 125 mg |
Excipients: sodium hydroxide solution 1M or hydrochloric acid solution 1M – to pH 6.5-7.5, water for injections – to 1 ml.
4 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
4 ml – ampoules (5) – contour cell packs (2) – cardboard packs.
4 ml – ampoules (10) – cardboard boxes.
Solution for intravenous and intramuscular administration in the form of a transparent, colorless liquid.
| 1 ml | |
| Citicoline sodium | 261.25 mg, |
| Equivalent to citicoline content | 250 mg |
Excipients: sodium hydroxide solution 1M or hydrochloric acid solution 1M – to pH 6.5-7.5, water for injections – to 1 ml.
4 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
4 ml – ampoules (5) – contour cell packs (2) – cardboard packs.
4 ml – ampoules (10) – cardboard boxes.
Solution for intravenous and intramuscular administration 125 mg/1 ml: amp. 4 ml 5 or 10 pcs.
Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 4 ml 5 or 10 pcs.
Marketing Authorization Holder
Pharmpotrebsoyuz, LLC (Russia)
Manufactured By
Bryntsalov-A, JSC (Russia)
Dosage Forms
|
Citicoline | Solution for intravenous and intramuscular administration 125 mg/1 ml: amp. 4 ml 5 or 10 pcs. |
| Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 4 ml 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Solution for intravenous and intramuscular administration in the form of a transparent, colorless liquid.
| 1 ml | |
| Citicoline (as sodium salt) | 125 mg |
Excipients: hydrochloric acid solution 1M or sodium hydroxide solution 1M (for pH adjustment), water for injections.
4 ml – ampoules of neutral colorless glass (5) – contour cell packs (1) – cardboard packs.
4 ml – ampoules of neutral colorless glass (5) – contour cell packs (2) – cardboard packs.
Solution for intravenous and intramuscular administration in the form of a transparent, colorless liquid.
| 1 ml | |
| Citicoline (as sodium salt) | 250 mg |
Excipients: hydrochloric acid solution 1M or sodium hydroxide solution 1M (for pH adjustment), water for injections.
4 ml – ampoules of neutral colorless glass (5) – contour cell packs (1) – cardboard packs.
4 ml – ampoules of neutral colorless glass (5) – contour cell packs (2) – cardboard packs.
Solution for intravenous and intramuscular administration 125 mg/ml: amp. 4 ml 5 pcs.
Solution for intravenous and intramuscular administration 250 mg/ml: amp. 4 ml 5 pcs.
Marketing Authorization Holder
Ecofarmplus, JSC (Russia)
Dosage Forms
|
Citicoline | Solution for intravenous and intramuscular administration 125 mg/ml: amp. 4 ml 5 pcs. |
| Solution for intravenous and intramuscular administration 250 mg/ml: amp. 4 ml 5 pcs. |
Dosage Form, Packaging, and Composition
Solution for intravenous and intramuscular administration in the form of a transparent, colorless or slightly yellowish-greenish liquid.
| 1 ml | |
| Citicoline sodium | 130.625 mg, |
| Equivalent to citicoline content | 125 mg |
Excipients: sodium hydroxide solution 1M/hydrochloric acid solution 1M – to pH 6.5-7.5, water for injections – to 1 ml.
4 ml – ampoules (5) – cardboard packs.
Solution for intravenous and intramuscular administration in the form of a transparent, colorless or slightly yellowish-greenish liquid.
| 1 ml | |
| Citicoline sodium | 261.25 mg, |
| Equivalent to citicoline content | 250 mg |
Excipients: sodium hydroxide solution 1M/hydrochloric acid solution 1M – to pH 6.5-7.5, water for injections – to 1 ml.
4 ml – ampoules (5) – cardboard packs.
Solution for intravenous and intramuscular administration 125 mg/1 ml: amp. 4 ml 3, 5, 6, 10, 12, 15, 20, or 25 pcs.
Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 4 ml 3, 5, 6, 10, 12, 15, 20, or 25 pcs.
Marketing Authorization Holder
Ellara, LLC (Russia)
Dosage Forms
|
Citicoline | Solution for intravenous and intramuscular administration 125 mg/1 ml: amp. 4 ml 3, 5, 6, 10, 12, 15, 20, or 25 pcs. |
| Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 4 ml 3, 5, 6, 10, 12, 15, 20, or 25 pcs. |
Dosage Form, Packaging, and Composition
Solution for intravenous and intramuscular administration colorless or with a brownish tint, transparent.
| 1 ml | |
| Citicoline sodium | 130.4 mg, |
| Calculated as Citicoline | 125 mg |
Excipients: hydrochloric acid solution 1M or sodium hydroxide solution 1M – to pH 6.5-7.5, water for injections – to 1 ml.
4 ml – ampoules of neutral glass (3) – contour cell packs (1) – cardboard packs.
4 ml – ampoules of neutral glass (3) – contour cell packs (2) – cardboard packs.
4 ml – ampoules of neutral glass (3) – contour cell packs (4) – cardboard packs.
4 ml – ampoules of neutral glass (3) – contour cell packs (5) – cardboard packs.
4 ml – ampoules of neutral glass (5) – contour cell packs (1) – cardboard packs.
4 ml – ampoules of neutral glass (5) – contour cell packs (2) – cardboard packs.
4 ml – ampoules of neutral glass (5) – contour cell packs (4) – cardboard packs.
4 ml – ampoules of neutral glass (5) – contour cell packs (5) – cardboard packs.
4 ml – ampoules of neutral glass (3) – cardboard packs.
4 ml – ampoules of neutral glass (5) – cardboard packs.
4 ml – ampoules of neutral glass (6) – cardboard packs.
4 ml – ampoules of neutral glass (10) – cardboard packs.
Solution for intravenous and intramuscular administration colorless or with a brownish tint, transparent.
| 1 ml | |
| Citicoline sodium | 260.7 mg, |
| Calculated as Citicoline | 250 mg |
Excipients: hydrochloric acid solution 1M or sodium hydroxide solution 1M – to pH 6.5-7.5, water for injections – to 1 ml.
4 ml – ampoules of neutral glass (3) – contour cell packs (1) – cardboard packs.
4 ml – ampoules of neutral glass (3) – contour cell packs (2) – cardboard packs.
4 ml – ampoules of neutral glass (3) – contour cell packs (4) – cardboard packs.
4 ml – ampoules of neutral glass (3) – contour cell packs (5) – cardboard packs.
4 ml – ampoules of neutral glass (5) – contour cell packs (1) – cardboard packs.
4 ml – ampoules of neutral glass (5) – contour cell packs (2) – cardboard packs.
4 ml – ampoules of neutral glass (5) – contour cell packs (4) – cardboard packs.
4 ml – ampoules of neutral glass (5) – contour cell packs (5) – cardboard packs.
4 ml – ampoules of neutral glass (3) – cardboard packs.
4 ml – ampoules of neutral glass (5) – cardboard packs.
4 ml – ampoules of neutral glass (6) – cardboard packs.
4 ml – ampoules of neutral glass (10) – cardboard packs.
Solution for intravenous and intramuscular injection 125 mg/ml
Solution for intravenous and intramuscular injection 250 mg/ml
Marketing Authorization Holder
Avexima JSC (Russia)
Manufactured By
Avexima Siberia LLC (Russia)
Dosage Forms
|
Citicoline Avexima | Solution for intravenous and intramuscular injection 125 mg/ml |
| Solution for intravenous and intramuscular injection 250 mg/ml |
Dosage Form, Packaging, and Composition
Solution for intravenous and intramuscular injection
| 1 ml | |
| Citicoline sodium | 130.625 mg, |
| Calculated as Citicoline | 125 mg |
4 ml – ampoules (10 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (5 pcs.) – cardboard packs – Prescription only
Solution for intravenous and intramuscular injection
| 1 ml | |
| Citicoline sodium | 261.25 mg, |
| Calculated as Citicoline | 250 mg |
4 ml – ampoules (10 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (5 pcs.) – cardboard packs – Prescription only
Oral solution 100 mg/1 ml: bottle 100 ml with dosing syringe
Marketing Authorization Holder
Medisorb, JSC (Russia)
Dosage Form
|
Citicoline Medisorb | Oral solution 100 mg/1 ml: bottle 100 ml with dosing syringe |
Dosage Form, Packaging, and Composition
Oral solution transparent, from colorless to yellowish-brownish tint, with a characteristic strawberry odor.
| 1 ml | |
| Citicoline sodium | 104.5 mg, |
| Calculated as Citicoline | 100 mg |
Excipients: liquid non-crystallizing sorbitol 70% – 200 mg, glycerol (glycerin) – 50 mg, methylparaben – 1.45 mg, propylparaben – 0.25 mg, sodium citrate dihydrate – 6 mg, sodium saccharin – 0.2 mg, strawberry flavor “Strawberry DEL’AR® 10.01.555″ – 0.408 mg, potassium sorbate – 3 mg, citric acid monohydrate – to pH 5.5-6.5, purified water – to 1 ml.
100 ml – polyethylene terephthalate bottles (1) with a dosing syringe – cardboard packs.
Film-coated tablets, 500 mg: 10, 14, 20, 28, 30, 40, 42, 50, 56, 60, 70, 84, 90 or 100 pcs.
Marketing Authorization Holder
Pharmacor Production, LLC (Russia)
Dosage Form
|
Citicoline-PHP | Film-coated tablets, 500 mg: 10, 14, 20, 28, 30, 40, 42, 50, 56, 60, 70, 84, 90 or 100 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white, oval, biconvex with a score.
| 1 tab. | |
| Citicoline sodium | 522.52 mg |
| Equivalent to citicoline content | 500 mg |
Excipients: microcrystalline cellulose, purified water, croscarmellose sodium, hydrogenated castor oil, colloidal silicon dioxide, magnesium stearate.
Film coating composition Opadry II85F48105 white (polyvinyl alcohol, macrogol, talc, titanium dioxide).
10 pcs. – contour cell pack (1) – cardboard packs.
10 pcs. – contour cell pack (2) – cardboard packs.
10 pcs. – contour cell pack (3) – cardboard packs.
10 pcs. – contour cell pack (4) – cardboard packs.
10 pcs. – contour cell pack (5) – cardboard packs.
10 pcs. – contour cell pack (6) – cardboard packs.
10 pcs. – contour cell pack (9) – cardboard packs.
14 pcs. – contour cell pack (1) – cardboard packs.
14 pcs. – contour cell pack (2) – cardboard packs.
14 pcs. – contour cell pack (3) – cardboard packs.
14 pcs. – contour cell pack (4) – cardboard packs.
14 pcs. – contour cell pack (5) – cardboard packs.
14 pcs. – contour cell pack (6) – cardboard packs.
20 pcs. – contour cell pack (1) – cardboard packs.
20 pcs. – contour cell pack (2) – cardboard packs.
20 pcs. – contour cell pack (3) – cardboard packs.
20 pcs. – contour cell pack (5) – cardboard packs.
Powder for oral solution, orange flavored 500 mg: 10, 20, or 30 pcs.
Powder for oral solution, honey and lemon flavored 500 mg: 10, 20, or 30 pcs.
Powder for oral solution, orange flavored 1000 mg: 10, 20, or 30 pcs.
Powder for oral solution, honey and lemon flavored 1000 mg: 10, 20, or 30 pcs.
Marketing Authorization Holder
Pharmacor Production, LLC (Russia)
Dosage Forms
|
Citicoline-PHP | Powder for oral solution, orange flavored 500 mg: 10, 20, or 30 pcs. |
| Powder for oral solution, honey and lemon flavored 500 mg: 10, 20, or 30 pcs. | ||
| Powder for oral solution, orange flavored 1000 mg: 10, 20, or 30 pcs. | ||
| Powder for oral solution, honey and lemon flavored 1000 mg: 10, 20, or 30 pcs. |
Dosage Form, Packaging, and Composition
Powder for oral solution (orange flavored) white or almost white with an orange aroma; the presence of white inclusions is allowed; upon dissolution, a transparent or opalescent solution with an orange aroma is formed; the presence of undissolved particles and flakes is allowed.
| 1 sachet | |
| Citicoline sodium | 522.5 mg |
| Equivalent to citicoline content | 500 mg |
Excipients: sorbitol, purified water, orange flavor, anhydrous colloidal silicon dioxide.
4 g – heat-sealed sachets of combined material (10) – cardboard packs.
4 g – heat-sealed sachets of combined material (20) – cardboard packs.
4 g – heat-sealed sachets of combined material (30) – cardboard packs.
Powder for oral solution (honey and lemon flavored) white or almost white with a honey and lemon aroma; the presence of white inclusions is allowed; upon dissolution, a transparent or opalescent solution with a honey and lemon aroma is formed; the presence of undissolved particles and flakes is allowed.
| 1 sachet | |
| Citicoline sodium | 522.5 mg |
| Equivalent to citicoline content | 500 mg |
Excipients: sorbitol, purified water, honey flavor, lemon flavor, anhydrous colloidal silicon dioxide.
4 g – heat-sealed sachets of combined material (10) – cardboard packs.
4 g – heat-sealed sachets of combined material (20) – cardboard packs.
4 g – heat-sealed sachets of combined material (30) – cardboard packs.
Powder for oral solution (orange flavored) white or almost white with an orange aroma; the presence of white inclusions is allowed; upon dissolution, a transparent or opalescent solution with an orange aroma is formed; the presence of undissolved particles and flakes is allowed.
| 1 sachet | |
| Citicoline sodium | 1045.5 mg |
| Equivalent to citicoline content | 1000 mg |
Excipients: sorbitol, purified water, orange flavor, anhydrous colloidal silicon dioxide.
4 g – heat-sealed sachets of combined material (10) – cardboard packs.
4 g – heat-sealed sachets of combined material (20) – cardboard packs.
4 g – heat-sealed sachets of combined material (30) – cardboard packs.
Powder for oral solution (honey and lemon flavored) white or almost white with a honey and lemon aroma; the presence of white inclusions is allowed; upon dissolution, a transparent or opalescent solution with a honey and lemon aroma is formed; the presence of undissolved particles and flakes is allowed.
| 1 sachet | |
| Citicoline sodium | 1045.5 mg |
| Equivalent to citicoline content | 1000 mg |
Excipients: sorbitol, purified water, honey flavor, lemon flavor, colloidal anhydrous silicon dioxide.
4 g – thermosealable sachets made of combined material (10) – cardboard packs.
4 g – thermosealable sachets made of combined material (20) – cardboard packs.
4 g – thermosealable sachets made of combined material (30) – cardboard packs.
Solution for intravenous and intramuscular injection 125 mg/ml
Solution for intravenous and intramuscular injection 250 mg/ml
Marketing Authorization Holder
Trivium-XXI, LLC (Russia)
Manufactured By
Armavir Biopharmaceutical Plant, FSE (Russia)
Dosage Forms
|
Citicoline Trivium® | Solution for intravenous and intramuscular injection 125 mg/ml |
| Solution for intravenous and intramuscular injection 250 mg/ml |
Dosage Form, Packaging, and Composition
Solution for intravenous and intramuscular injection
| 1 ml | |
| Citicoline sodium | 130.625 mg, |
| In terms of Citicoline | 125 mg |
4 ml – ampoules (10 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (100 pcs.) – cardboard boxes – Prescription only
4 ml – ampoules (100 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (125 pcs.) – cardboard boxes – Prescription only
4 ml – ampoules (125 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (200 pcs.) – cardboard boxes – Prescription only
4 ml – ampoules (200 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (250 pcs.) – cardboard boxes – Prescription only
4 ml – ampoules (250 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (5 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (50 pcs.) – cardboard boxes – Prescription only
4 ml – ampoules (50 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (500 pcs.) – cardboard boxes – Prescription only
4 ml – ampoules (500 pcs.) – cardboard packs – Prescription only
Solution for intravenous and intramuscular injection
| 1 ml | |
| Citicoline sodium | 261.25 mg |
| Equivalent to citicoline content | 250 mg |
4 ml – ampoules (10 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (100 pcs.) – cardboard boxes – Prescription only
4 ml – ampoules (100 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (125 pcs.) – cardboard boxes – Prescription only
4 ml – ampoules (125 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (200 pcs.) – cardboard boxes – Prescription only
4 ml – ampoules (200 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (250 pcs.) – cardboard boxes – Prescription only
4 ml – ampoules (250 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (5 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (50 pcs.) – cardboard boxes – Prescription only
4 ml – ampoules (50 pcs.) – cardboard packs – Prescription only
4 ml – ampoules (500 pcs.) – cardboard boxes – Prescription only
4 ml – ampoules (500 pcs.) – cardboard packs – Prescription only
Solution for intravenous and intramuscular injection 125 mg/ml: 4 ml amp., 3, 5, 6 or 10 pcs.
Solution for intravenous and intramuscular injection 250 mg/ml: 4 ml amp., 3, 5, 6 or 10 pcs.
Marketing Authorization Holder
Velpharm, LLC (Russia)
Dosage Forms
|
Citicoline Velpharm | Solution for intravenous and intramuscular injection 125 mg/ml: 4 ml amp., 3, 5, 6 or 10 pcs. |
| Solution for intravenous and intramuscular injection 250 mg/ml: 4 ml amp., 3, 5, 6 or 10 pcs. |
Dosage Form, Packaging, and Composition
Solution for IV and IM administration as a clear, colorless liquid.
| 1 ml | |
| Citicoline sodium | 130.63 mg, |
| Equivalent to citicoline content | 125 mg |
Excipients: 1M hydrochloric acid solution or 1M sodium hydroxide solution, water for injections.
4 ml – ampoules (3) – contour cell packs (1) – cardboard packs.
4 ml – ampoules (3) – contour cell packs (2) – cardboard packs.
4 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
4 ml – ampoules (5) – contour cell packs (2) – cardboard packs.
4 ml – ampoules – contour cell packs (20) – cardboard boxes (for hospitals).
4 ml – ampoules – contour cell packs (48) – cardboard boxes (for hospitals).
4 ml – ampoules – contour cell packs (50) – cardboard boxes (for hospitals).
4 ml – ampoules – contour cell packs (96) – cardboard boxes (for hospitals).
4 ml – ampoules – contour cell packs (100) – cardboard boxes (for hospitals).
Solution for IV and IM administration as a clear, colorless liquid.
| 1 ml | |
| Citicoline sodium | 261.25 mg, |
| Equivalent to citicoline content | 250 mg |
Excipients: 1M hydrochloric acid solution or 1M sodium hydroxide solution, water for injections.
4 ml – ampoules (3) – contour cell packs (1) – cardboard packs.
4 ml – ampoules (3) – contour cell packs (2) – cardboard packs.
4 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
4 ml – ampoules (5) – contour cell packs (2) – cardboard packs.
4 ml – ampoules – contour cell packs (20) – cardboard boxes (for hospitals).
4 ml – ampoules – contour cell packs (48) – cardboard boxes (for hospitals).
4 ml – ampoules – contour cell packs (50) – cardboard boxes (for hospitals).
4 ml – ampoules – contour cell packs (96) – cardboard boxes (for hospitals).
4 ml – ampoules – contour cell packs (100) – cardboard boxes (for hospitals).
Solution for intravenous and intramuscular injection 500 mg/4 ml: amp., 3, 5, 6 or 10 pcs.
Solution for intravenous and intramuscular injection 1000 mg/4 ml: amp., 3, 5, 6 or 10 pcs.
Marketing Authorization Holder
Binnopharm JSC (Russia)
Dosage Forms
|
Citicoline-Alium | Solution for intravenous and intramuscular injection 500 mg/4 ml: amp., 3, 5, 6 or 10 pcs. |
| Solution for intravenous and intramuscular injection 1000 mg/4 ml: amp., 3, 5, 6 or 10 pcs. |
Dosage Form, Packaging, and Composition
Solution for IV and IM administration as a clear, colorless liquid.
| 1 amp. | |
| Citicoline sodium | 522.5 mg, |
| Equivalent to citicoline content | 500 mg |
Excipients: 1M hydrochloric acid solution or 1M sodium hydroxide solution – to pH 6.5-7.5, water for injections – to 4 ml.
4 ml – ampoules made of neutral colorless glass (3) – contour cell packs (1) – cardboard packs.
4 ml – ampoules made of neutral colorless glass (3) – contour cell packs (2) – cardboard packs.
4 ml – ampoules made of neutral colorless glass (5) – contour cell packs (1) – cardboard packs.
4 ml – ampoules made of neutral colorless glass (5) – contour cell packs (2) – cardboard packs.
Solution for IV and IM administration as a clear, colorless liquid.
| 1 amp. | |
| Citicoline sodium | 1045 mg, |
| Equivalent to citicoline content | 1000 mg |
Excipients: 1M hydrochloric acid solution or 1M sodium hydroxide solution – to pH 6.5-7.5, water for injections – to 4 ml.
4 ml – ampoules made of neutral colorless glass (3) – contour cell packs (1) – cardboard packs.
4 ml – ampoules made of neutral colorless glass (3) – contour cell packs (2) – cardboard packs.
4 ml – ampoules made of neutral colorless glass (5) – contour cell packs (1) – cardboard packs.
4 ml – ampoules made of neutral colorless glass (5) – contour cell packs (2) – cardboard packs.
Solution for intravenous and intramuscular injection 125 mg/1 ml: amp. 4 ml, 3, 5, 10 or 20 pcs.
Solution for intravenous and intramuscular injection 250 mg/1 ml: amp. 4 ml, 3, 5, 10 or 20 pcs.
Marketing Authorization Holder
Mir Chemical and Pharmaceutical Concern, LLC (Russia)
Manufactured By
NPC Eskom, PJSC (Russia)
Dosage Forms
|
Citicoline-Escom | Solution for intravenous and intramuscular injection 125 mg/1 ml: amp. 4 ml, 3, 5, 10 or 20 pcs. |
| Solution for intravenous and intramuscular injection 250 mg/1 ml: amp. 4 ml, 3, 5, 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
Solution for IV and IM administration as a colorless, clear liquid.
| 1 ml | |
| Citicoline sodium | 130.63 mg, |
| In terms of Citicoline | 125 mg |
Excipients: 1M hydrochloric acid solution or 1M sodium hydroxide solution – to pH 6.5-7.5, water for injections – to 1 ml.
4 ml – glass ampoules (3) – contour cell packs (1) – cardboard packs.
4 ml – glass ampoules (5) – contour cell packs (1) – cardboard packs.
4 ml – glass ampoules (5) – contour cell packs (2) – cardboard packs.
4 ml – glass ampoules (5) – contour cell packs (4) – cardboard packs.
4 ml – glass ampoules (10) – contour cell packs (1) – cardboard packs.
4 ml – glass ampoules (10) – contour cell packs (2) – cardboard packs.
4 ml – glass ampoules (10) – cardboard packs.
Solution for IV and IM administration as a colorless, clear liquid.
| 1 ml | |
| Citicoline sodium | 261.26 mg, |
| In terms of Citicoline | 250 mg |
Excipients: 1M hydrochloric acid solution or 1M sodium hydroxide solution – to pH 6.5-7.5, water for injections – to 1 ml.
4 ml – glass ampoules (3) – contour cell packs (1) – cardboard packs.
4 ml – glass ampoules (5) – contour cell packs (1) – cardboard packs.
4 ml – glass ampoules (5) – contour cell packs (2) – cardboard packs.
4 ml – glass ampoules (5) – contour cell packs (4) – cardboard packs.
4 ml – glass ampoules (10) – contour cell packs (1) – cardboard packs.
4 ml – glass ampoules (10) – contour cell packs (2) – cardboard packs.
4 ml – glass ampoules (10) – cardboard packs.
Oral solution 100 mg/ml: 30 ml or 100 ml fl. 1, 3 or 6 pcs.
Marketing Authorization Holder
Vertex, JSC (Russia)
Dosage Form
|
Citicoline-Vertex | Oral solution 100 mg/ml: 30 ml or 100 ml fl. 1, 3 or 6 pcs. |
Dosage Form, Packaging, and Composition
Oral solution as a clear or slightly opalescent colorless or light yellow liquid with a characteristic strawberry odor.
| 1 ml | |
| Citicoline sodium | 104.5 mg, |
| Equivalent to citicoline content | 100 mg |
Excipients: sorbitol – 200 mg, glycerol – 50 mg, sodium citrate (sodium citrate dihydrate) – 6 mg, potassium sorbate – 3 mg, methylparaben – 1.45 mg, strawberry flavor 1487S – 0.4 mg, propylparaben – 0.25 mg, sodium saccharin – 0.2 mg, citric acid monohydrate – to pH 5 – 7, purified water – to 1 ml.
30 ml – bottles (1) – cardboard packs.
30 ml – bottles (3) – cardboard packs.
30 ml – bottles (6) – cardboard packs.
100 ml – bottles (1) – cardboard packs.
100 ml – bottles (3) – cardboard packs.
100 ml – bottles (6) – cardboard packs.
![Citicoline [Tablets, Solution, Powder] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Citicoline [Tablets, Solution, Powder] 2")